Specialized in fusion molecules based on secondary metabolites from eukaryotes.

Develops enzyme-powered topical products for improved management of skin conditions

formerly known as Arxx Therapeutics, develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis